RET M918T
|
Thyroid Gland Medullary Carcinoma
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
cabozantinib capsule Sensitive: A2 - Guideline
|
cabozantinib capsule Sensitive: A2 - Guideline
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
pralsetinib Sensitive: C3 – Early Trials
|
pralsetinib Sensitive: C3 – Early Trials
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
sorafenib Sensitive: C3 – Early Trials
|
sorafenib Sensitive: C3 – Early Trials
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
selpercatinib Sensitive: C3 – Early Trials
|
selpercatinib Sensitive: C3 – Early Trials
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
everolimus + vandetanib Sensitive: C4 – Case Studies
|
everolimus + vandetanib Sensitive: C4 – Case Studies
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
everolimus Sensitive: C4 – Case Studies
|
everolimus Sensitive: C4 – Case Studies
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
vandetanib Sensitive: C4 – Case Studies
|
vandetanib Sensitive: C4 – Case Studies
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
sunitinib Sensitive: C4 – Case Studies
|
sunitinib Sensitive: C4 – Case Studies
|
RET M918T
|
Thyroid Gland Carcinoma
|
RET M918T
|
Thyroid Gland Carcinoma
|
XMD15-44 Sensitive: D – Preclinical
|
XMD15-44 Sensitive: D – Preclinical
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
RET M918T
|
Thyroid Gland Medullary Carcinoma
|
AMG 706 Resistant: D – Preclinical
|
AMG 706 Resistant: D – Preclinical
|
RET M918T
|
Thyroid Gland Carcinoma
|
RET M918T
|
Thyroid Gland Carcinoma
|
HG-6-63-01 Sensitive: D – Preclinical
|
HG-6-63-01 Sensitive: D – Preclinical
|
RET M918T
|
Thyroid Gland Papillary Carcinoma
|
RET M918T
|
Thyroid Gland Papillary Carcinoma
|
AZD1480 Sensitive: D – Preclinical
|
AZD1480 Sensitive: D – Preclinical
|
RET M918T
|
Thyroid Gland Carcinoma
|
RET M918T
|
Thyroid Gland Carcinoma
|
ALW-II-41-27 Sensitive: D – Preclinical
|
ALW-II-41-27 Sensitive: D – Preclinical
|